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Combined modality treatment using a non-platinum-containing 
regimen and concurrent radiotherapy in the treatment of locally-
advanced non-small cell lung cancer
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Background: In the era of targeted agents, combined chemoradio-
therapy remains standard of care for non-resectable stage III non-small 
cell lung cancer (NSCLC). While recognizing that we have probably 
reached a plateau in terms of treatment results using this strategy, it is 
still imperative to reduce toxicities while not compromising efﬁcacy. 
This study aims to evaluate a non-platinum-containing regimen used in 
conjunction with radiotherapy.
Methods: Patients with histologically proven, non-resectable stage 
III NSCLC are eligible for the study. They must be above 18 years 
old, have good performance status, and have adequate bone marrow, 
renal and hepatic function. Patients will receive 2 cycles of induction 
vinorelbine (25mg/m2) and gemcitabine (1000mg/m2) given on days 1 
and 8 every 21 days, followed by radiotherapy 60-66Gy with concur-
rent weekly vinorelbine (15mg/m2). The primary objective is to assess 
the response rate to this regimen and secondary objectives to assess 
tolerability and toxicity.
Results: We have completed the target accrual of 42 patients. There 
are 31 males and 11 females. The median age is 65, range of 41 to 
79. Sixty-one percent has stage IIIB disease and 38.9% has stage IIIA 
disease. Forty-four percent of the patients have adenocarcinoma and 
25% of patients have squamous cell carcinoma. Fifteen patients (36%) 
achieved a partial response after induction chemotherapy. After chemo-
radiotherapy, 7 patients had complete response and 19 patients had 
partial response, giving an overall response rate of 62%. Toxicity data 
is available for 36 patients. Nine patients(25%) had grade 3 or 4 neutro-
penia, 4 patients(11%) had grade 3 esophagitis and 3 patients(8%) had 
grade 3 fatigue.
Conclusion: The toxicities of this regimen are low and the response 
rate is comparable to similar treatment schedules with platinum-based 
chemotherapy.
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Background: concurrent chemoradiotherapy treatment is standard of 
care for patients with stage III NSCLC and a good performance status. 
Optimal chemotherapy have yet to be deﬁned and the role of surgery is 
still unclear.
This prospective study analysed the feasibility and efﬁcacy of weekly 
docetaxel/cisplatin (DC) and concurrent involved-ﬁeld thoracic radio-
therapy (CRT) followed by surgery in good performance status patients 
with stage IIIA/B NSCLC. Primary endpoint is radiological response 
of DC and CRT. Secondary endpoints included toxicity, efﬁcacy of 
surgery, postoperative morbidity and mortality, time to progression and 
overall survival.
Methods: DC consisted of IV docetaxel 20 mg/m2 and cisplatin 20mg/
m2 at days 1,8,15,22,29 and 36. CRT was given in once-daily fractions 
of 1.8 Gy, 5 fractions a week to a total dose of 45 Gy during days 8 to 
36. CT-based planning was used to minimise radiation to the contra 
lateral lung. Invasive and non-invasive investigations were performed 
after induction treatment in order to restage the mediastinum. when me-
diastinal down staging was achieved, surgery was performed in order to 
achieve radical resection. 
Results: Between January 2005 until August 2006, 45 patients were 
included, of whom 43 patients were evaluable. Stage IIIB disease was 
present in 18 patients (cT4N2=10, cT4N0/N1=5 and cN3=3) and 25 had 
stage IIIA-N2 disease. A radiological response was seen in 20 patients 
(47%) and 8 (19%) showed progressive disease. Toxicity was mild.
Explorative thoracotomy was performed in 25 (58%) patients. Of 
these, 15 were initially staged as IIIA and ten as stage IIIB. Twenty-one 
patients (49%) underwent a radical resection without residual medias-
tinal malignant disease, and ten pneumonectomies (8 left sided) were 
performed. Four patients showed complete pathological response. The 
30 days mortality after operation was 4% (one patient) due to ARDS. 
The median follow up time was 9.9 months. Seventeen patients of 43 
showed progression (40%), of which 13 patients developed distant 
metastases (30%).
Conclusion: Weekly DC and involved-ﬁeld CRT is possible in stage 
III NSCLC, with limited toxicity and nearly half of the treated patients 
(47%) could undergo a radical surgical resection (R0) without residual 
mediastinal malignant disease. Due to low dose chemotherapy almost 
40% of the whole group showed progression of which 30% developed 
distant metastases.
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Background: The therapeutic effects of anticancer drugs on large cell 
neuroendocrine carcinoma (LCNEC), which is classiﬁed as small cell 
lung cancer under the WHO classiﬁcation, have not been established, 
and no consensus on postoperative adjuvant chemotherapy for it has 
been reached. However, last year, a platinum-based regimen with etop-
side for small cell lung cancer, as postoperative adjuvant chemotherapy 
for LCNEC, was reported to signiﬁcantly improve the prognosis, 
requiring follow-up studies.
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Objective: To evaluate the effects of postoperative anticancer chemo-
therapy for small cell lung cancer on LCNEC.
Methods: Twenty-four patients who had undergone resection of 
LCNEC in our hospital between 1986 and 2004 were classiﬁed, accord-
ing to the presence or absence of postoperative adjuvant chemotherapy 
and to its regimen, into group A which received two or more courses 
of a platinum-based regimen with VP-16 or CPT-11 for small cell lung 
cancer, group B which received other regimens, and group C which re-
ceived no postoperative adjuvant chemotherapy, and evaluated in terms 
of 5-year recurrence-free survival and 5-year survival rates.
Results: The subjects consisted of 24 men and 2 women, with a mean 
age of 68 years, and all were smokers. Six patients had stage I cancer, 4 
stage II cancer, 13 stage III cancer, and 1 stage IV cancer. Six patients 
(25%) belonged to group A, 4 (1 received MVP 2 courses, 1 CAV 1 
courses, and 2 UFT courses) to group B, and 14 to group C. The 5-year 
recurrence-free survival and 5-year survival rates in group A were 50% 
each, whereas all patients in group B died within 2 years, and the 5-
year recurrence-free survival and 5-year survival rates in group C were 
25% and 34%, respectively.
Discussion: No signiﬁcant intergroup differences were observed, be-
cause of the small number of patients studied. However, the prognosis 
in group A was slightly better than that in groups B and C. Since the 
present study evaluated a small number of patients in all stages of can-
cer, the current issue remained unresolved. Therefore, further studies 
are needed in more patients.
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Background: We have reported an efﬁcacy of the combination of 
cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for 
the treatment of previously untreated patients with non-small cell lung 
cancer (NSCLC). Concurrent radiation applied to cisplatin-based che-
motherapy with new anticancer agents is expected for locally advanced 
NSCLC. We evaluated the efﬁcacy and safety of cisplatin and weekly 
docetaxel combined with thoracic radiotherapy for patients with Stage 
III advanced NSCLC. 
Methods: We identiﬁed 34 eligible patients with locally advanced 
NSCLC and good performance status (PS) (ECOG; 0 or 1) who had 
not received prior treatment and who were under 75 years old. Their 
median age was 63 years (range, 45-74 years), 32 patients were male 
(94.1%), two (5.9%) were female, 30 (88.2%) had PS 0, 4 (11.8%) had 
PS 1, 3 had Stage IIIA (8.9%), and 31 had Stage IIIB (91.1%). Tumor 
histology included adenocarcinoma (55.9 %) and epidermoid (41.2 %). 
The patients received intravenous infusions of docetaxel (20 mg/m2, 
days 1, 8, 15) and cisplatin (80mg/m2, day 1) with standard thoracic 
concurrent radiation (60Gy, 2Gy/day).
Result: Grade 3/4 neutropenia was recorded in four patients (12 %), 
but there were no episodes of neutropenic fever. Nonhematologic toxic-
ities were also mild, consisting mainly in grade II anorexia. Esophagitis 
and pulmonary toxicities over Grade 3 were observed in 18 % and 12 
%, respectively. One complete response and 19 partial responses were 
observed and the objective response rate was 59.6 %. The median sur-
vival time was 26.4 months, and the 1-year survival rate was 76.0 %. 
Conclusion: Cisplatin with weekly administration of docetaxel com-
bined with concurrent radiotherapy is a feasible and effective regimen 
against advanced NSCLC.
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Background: In locally advanced non-small cell lung cancer(NSCLC), 
concurrent chemoradiotherapy(CCRT) becomes the leading therapeutic 
modality. But there are still many controversies in the chemotherapeu-
tic regimens and in the radiation methods. 
Materials and Methods: 27 NSCLC patients of clinical stage IIIB, 2 
patients with stage IIIA were enrolled since December 2002. The per-
formance status of ECOG grade 0 or 1 was in 22 patients(75.9%) and 
the others were grade 2. Squamous cell cancer was the most common 
(62%), followed by adenocarcinoma (31%). Cisplatin(30mg/m2) and 
gemcitabine(500mg/m2) were administered every two weeks while 50.4 
Gy(28 fractions) was irradiated on the tumor site. Booster irradiation of 
18 Gy (10 fractions) was administered unless the disease progressed. 
Two or three cycles of consolidation chemotherapy were done with 
gemcitabine(1200mg/m2 1st and 8thday) and cisplatin(60mg/m2) every 
three weeks. 
Results: During CCRT, severe esophagitis(>grade III) was serious 
complication(51.6%), followed by granulocytopenia(72.2%) and 
pneumonitis(20.7%). But they were mostly grade 2 and well managed 
by medical treatments and no patients withheld the treatment. After the 
consolidation chemotherapy, 3 patients(10.3%) had complete remis-
sion, 21 patients (72.4%) showed partial remission, and in 4 patients, 
the disease was stable, and in 1 patients it progressed. 
Median survival time was 16 months( 95% CI;2.4-39.2 months), The 
survival rates in one, two, and three years are 62.7%, 43.9%, 20%, 
respectively. 
Conclusion: The response rate and survival time of biweekly gem-
citabine plus cisplatin chemotherapy with concurrent radiotherapy 
was encouraging in patients with locally advanced NSCLC. However, 
treatment related toxicities were signiﬁcant, thus further modiﬁcation 
of therapy seems to be warranted. 
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